Logo image of MDXH

MDXHEALTH (MDXH) Stock Fundamental Analysis

NASDAQ:MDXH - Nasdaq - BE0974461940 - Common Stock - Currency: USD

2.19  -0.02 (-0.82%)

Fundamental Rating

3

MDXH gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 555 industry peers in the Biotechnology industry. MDXH may be in some trouble as it scores bad on both profitability and health. MDXH is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

MDXH had negative earnings in the past year.
MDXH had a negative operating cash flow in the past year.
MDXH had negative earnings in each of the past 5 years.
In the past 5 years MDXH always reported negative operating cash flow.
MDXH Yearly Net Income VS EBIT VS OCF VS FCFMDXH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

With a decent Return On Assets value of -33.44%, MDXH is doing good in the industry, outperforming 63.24% of the companies in the same industry.
Looking at the Return On Equity, with a value of -979.67%, MDXH is doing worse than 81.80% of the companies in the same industry.
Industry RankSector Rank
ROA -33.44%
ROE -979.67%
ROIC N/A
ROA(3y)-31.55%
ROA(5y)-44.62%
ROE(3y)-441.71%
ROE(5y)-376.22%
ROIC(3y)N/A
ROIC(5y)N/A
MDXH Yearly ROA, ROE, ROICMDXH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

Looking at the Gross Margin, with a value of 61.69%, MDXH is in the better half of the industry, outperforming 79.10% of the companies in the same industry.
In the last couple of years the Gross Margin of MDXH has grown nicely.
MDXH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.37%
GM growth 5YN/A
MDXH Yearly Profit, Operating, Gross MarginsMDXH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

MDXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MDXH has been increased compared to 1 year ago.
Compared to 5 years ago, MDXH has more shares outstanding
Compared to 1 year ago, MDXH has a worse debt to assets ratio.
MDXH Yearly Shares OutstandingMDXH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
MDXH Yearly Total Debt VS Total AssetsMDXH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -2.26, we must say that MDXH is in the distress zone and has some risk of bankruptcy.
MDXH's Altman-Z score of -2.26 is in line compared to the rest of the industry. MDXH outperforms 51.17% of its industry peers.
MDXH has a Debt/Equity ratio of 13.81. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 13.81, MDXH is doing worse than 84.68% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 13.81
Debt/FCF N/A
Altman-Z -2.26
ROIC/WACCN/A
WACC9.97%
MDXH Yearly LT Debt VS Equity VS FCFMDXH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 2.00 indicates that MDXH has no problem at all paying its short term obligations.
MDXH has a worse Current ratio (2.00) than 76.22% of its industry peers.
A Quick Ratio of 1.92 indicates that MDXH should not have too much problems paying its short term obligations.
MDXH's Quick ratio of 1.92 is on the low side compared to the rest of the industry. MDXH is outperformed by 75.68% of its industry peers.
Industry RankSector Rank
Current Ratio 2
Quick Ratio 1.92
MDXH Yearly Current Assets VS Current LiabilitesMDXH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 17.86% over the past year.
The Revenue has grown by 25.85% in the past year. This is a very strong growth!
The Revenue has been growing by 50.17% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)17.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.71%
Revenue 1Y (TTM)25.85%
Revenue growth 3Y59.39%
Revenue growth 5Y50.17%
Sales Q2Q%22.48%

3.2 Future

Based on estimates for the next years, MDXH will show a very strong growth in Earnings Per Share. The EPS will grow by 26.91% on average per year.
The Revenue is expected to grow by 19.69% on average over the next years. This is quite good.
EPS Next Y61.77%
EPS Next 2Y34.67%
EPS Next 3Y26.91%
EPS Next 5YN/A
Revenue Next Year23.05%
Revenue Next 2Y20.33%
Revenue Next 3Y19.2%
Revenue Next 5Y19.69%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
MDXH Yearly Revenue VS EstimatesMDXH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M
MDXH Yearly EPS VS EstimatesMDXH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -1 -2 -3 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MDXH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MDXH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDXH Price Earnings VS Forward Price EarningsMDXH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDXH Per share dataMDXH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as MDXH's earnings are expected to grow with 26.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.67%
EPS Next 3Y26.91%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MDXH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MDXHEALTH

NASDAQ:MDXH (7/3/2025, 7:47:57 PM)

2.19

-0.02 (-0.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-14 2025-08-14/amc
Inst Owners43.04%
Inst Owner Change0%
Ins Owners8.29%
Ins Owner ChangeN/A
Market Cap59.76M
Analysts86.67
Price Target5.66 (158.45%)
Short Float %0.17%
Short Ratio0.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.39%
Min EPS beat(2)-43.29%
Max EPS beat(2)28.51%
EPS beat(4)1
Avg EPS beat(4)-28.85%
Min EPS beat(4)-55.38%
Max EPS beat(4)28.51%
EPS beat(8)1
Avg EPS beat(8)-62.93%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1.39%
Min Revenue beat(2)-1.05%
Max Revenue beat(2)3.83%
Revenue beat(4)3
Avg Revenue beat(4)3.39%
Min Revenue beat(4)-1.05%
Max Revenue beat(4)6.42%
Revenue beat(8)7
Avg Revenue beat(8)4.87%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.31%
PT rev (3m)-8.11%
EPS NQ rev (1m)3.69%
EPS NQ rev (3m)-15.2%
EPS NY rev (1m)3.19%
EPS NY rev (3m)12.12%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)-0.32%
Revenue NY rev (1m)0.06%
Revenue NY rev (3m)0.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.43
P/FCF N/A
P/OCF N/A
P/B 10.01
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.15
EYN/A
EPS(NY)-0.24
Fwd EYN/A
FCF(TTM)-0.64
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS5.04
BVpS0.22
TBVpS-2.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.44%
ROE -979.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.69%
FCFM N/A
ROA(3y)-31.55%
ROA(5y)-44.62%
ROE(3y)-441.71%
ROE(5y)-376.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.37%
GM growth 5YN/A
F-Score3
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity 13.81
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.31%
Cap/Sales 1.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2
Quick Ratio 1.92
Altman-Z -2.26
F-Score3
WACC9.97%
ROIC/WACCN/A
Cap/Depr(3y)61.59%
Cap/Depr(5y)46.12%
Cap/Sales(3y)6.93%
Cap/Sales(5y)5.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.71%
EPS Next Y61.77%
EPS Next 2Y34.67%
EPS Next 3Y26.91%
EPS Next 5YN/A
Revenue 1Y (TTM)25.85%
Revenue growth 3Y59.39%
Revenue growth 5Y50.17%
Sales Q2Q%22.48%
Revenue Next Year23.05%
Revenue Next 2Y20.33%
Revenue Next 3Y19.2%
Revenue Next 5Y19.69%
EBIT growth 1Y8.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year98.64%
EBIT Next 3Y44.48%
EBIT Next 5Y41.61%
FCF growth 1Y21.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.8%
OCF growth 3YN/A
OCF growth 5YN/A